An interventional study of Extended Pelvic Lymph Node Dissection in Prostate Cancer Surgery and Prostate Cancers, sponsored by University Hospital, Basel, Switzerland. Recruiting at 15 sites in Switzerland. Open to male participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-07-03.
Sponsored by University Hospital, Basel, Switzerland · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 136 studies in Prostatic Neoplasms with a site in Switzerland — 40 open to participants now, 58 under way, 20 of them phase 3. Prostatic Neoplasms · Switzerland.
Among the 136 studies in Prostatic Neoplasms with a site in Switzerland, this one is the 35th largest by planned enrollment of the 107 interventional ones that give a count, is one of 9 that started in 2025, is one of 23 with no phase, reaches primary completion later than 21 of the 57 other live ones, and was the 114th registered.
7,055 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.
Browse Prostatic Neoplasms studies →40 of the 136 studies in Prostatic Neoplasms with a site in Switzerland are open now. Recruiting first, the newest first:
Novartis Pharmaceuticals · Sites in Switzerland
Men only
AstraZeneca · Sites in Switzerland, United States, Austria and 18 more countries
Ages 18+ · Men only
Massimo Valerio · Sites in Switzerland
Ages 18+ · Men only
University of Zurich · Sites in Switzerland
Ages 18+ · Men only
University Hospital, Basel, Switzerland · Sites in Switzerland
Ages 50+ · Men only · Healthy volunteers
A study can be open while its sites in Switzerland have not opened yet or have stopped. Only those recruiting at a site in Switzerland →
Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.
This study: 18 Years and older · male · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
136 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 19 · Phase 2 31 · Phase 3 43 · Phase 4 3
First in 1992; this study’s year is marked. 9 started in 2025.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 400 is above the median of 60 across 5,358 interventional studies indexed under Prostatic Neoplasms.
Median enrollment 140 across the 107 interventional studies, 219 across the 28 observational. Of the 71 that completed or were terminated, 16 (23%) have results posted.
This tab as a report to print or save as PDF → With an account.
44 of 136 have an industry lead sponsor. The 10 most frequent:
University Hospital, Basel, Switzerland is the lead sponsor of 990 studies on the registry; 189 are open to participants now.
University Hospital, Basel, Switzerland has 7 studies filed under Prostatic Neoplasms — fewer than ten, so there is no comparison to draw.
8 of the studies in Prostatic Neoplasms with a site in Switzerland that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03903835Phase 3Karolinska InstitutetProBio: A Biomarker Driven Study in Patients With Metastatic Prostate Cancer | 2026-12 |
| NCT07455097Heinrich-Heine University, DuesseldorfCOMBINED PSMA-PET/CT AND MRI STAGING IN INTERMEDIATE AND HIGH-RISK PATIENTS PROSTATA-CANCER (COMBINE-P) | 2026-12-31 |
| NCT05850182Oncology Institute of Southern SwitzerlandLifestyle Intervention in Patients With Metastatic Prostate Cancer | 2026-12-31 |
| NCT04543799Oncology Institute of Southern SwitzerlandEvaluation of Sleep Quality in Prostate Cancer Patients Undergoing Treatment With Hormonal Therapeutic Approaches and in Patients With Full-resected Early Breast Cancer | 2026-12-31 |
| NCT06776172University Hospital, Basel, SwitzerlandExtended vs. No Pelvic Lymph Node Dissection During Radical Prostatectomy. DISSECTION 2.0. | 2027-02 |
Add all 8 to your calendar (.ics) → With an account.
Among the 136 studies in Prostatic Neoplasms with a site in Switzerland, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The aim of the DISSECTION 2.0 study is to determine whether extended pelvic lymph node dissection (ePLND) provides a therapeutic benefit for high-risk prostate cancer patients by improving cancer staging and potentially removing micrometastatic disease, ultimately improving their outcomes.
Prostate cancer is the second most common cancer in men globally and a major cause of cancer deaths in Europe. For men with localized prostate cancer (PCa) and a life expectancy of over 10 years, radical prostatectomy (RP) is the standard treatment. It improves survival compared to conservative management. However, there is debate about de benefit of pelvic lymph node dissection (PLND), the removal of lymph nodes in the pelvis, during RP. While PLND can be omitted in low risk PCa patients, extended PLND (ePLND) is recommended in PCa patients at high-risk for recurrence in order to improve nodal staging The DISSECTION 2.0 study aims to investigate whether extended PLND (ePLND) provides additional benefits for men with high-risk PCa. The hypothesis is that ePLND might help by removing undetectable cancer cells (micrometastases) in the lymph nodes or by better staging the disease for treatment planning. While imaging techniques like PSMA-PET are good at detecting cancer spread, they still miss approximately 60% of cancer-bearing lymph nodes, leaving room for ePLND to potentially improve outcomes.
ePLND involves removing more lymph nodes than standard PLND, leading to better detection of cancer spread. However, it also increases surgery time and complications slightly, though serious complications are rare.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
High-risk prostate cancer defined as:
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Life expectancy
The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Biopsy and archival tissue
A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.
Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ECOG performance status
A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.
Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Adjuvant and neoadjuvant
Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Procedure: Extended Pelvic Lymph Node Dissection
Extended pelvic lymph node dissection during radical prostatectomy
Also known as: Extended Lymph Node Dissection
Prostate specific antigen (PSA) persistence
defined as failure to reach a PSA value of \<0.1 ng/ml
Time frame: 3 month (+/- 2 weeks) postoperatively
Biochemical recurrence free survival (BCRFS)
time from randomization to biochemical recurrence, defined as serum PSA level ≥ 0.2 ng/ml
Time frame: within 24 months post surgery
PSA persistence (PSAP) above detection limit
cut-off ≥ 0.03 ng/ml
Time frame: postoperative to the end of the study at 10-15 years
Initiation time of adjuvant or salvage therapies
Calculated from randomization to the start of any adjuvant or salvage therapy. Salvage radiotherapy (SRT) to the prostatic fossa only excluding lymphatics and without androgen deprivation therapy) will not count as an event for this endpoint if: * A PSMA-PET-computed tomography prior to SRT was negative for disease beyond the prostatic fossa, and * the SRT led to a PSA \<0.1 ng/ml (PSAP) or ≤ 0.2 ng/ml (biochemical recurrence-free survival, BCRFS), respectively.
Time frame: postoperative to the end of the study at 10-15 years
Time to loco-regional recurrence
Calculated from randomization until the first local (prostate bed) or regional (within the extent of the ePLND template) recurrence.
Time frame: from randomization to end of study at 10-15 years
Localization of progression
Prostate-specific membrane antigen positron emission tomography (PSMA-PET)
Time frame: from randomization to end of study at 10-15 years
Time to distant metastasis
Calculated from randomization until the first occurrence of distant metastasis.
Time frame: postoperative to the end of the study at 10-15 years
Prostate cancer-specific survival
death due to prostate cancer
Time frame: postoperative to the end of the study at 10-15 years
Overall survival
death from any cause
Time frame: postoperative to the end of the study at 10-15 years
Intraoperative complications
Documented using the CLASSintra classification
Time frame: during surgery
Postoperative complications
Assessed using the Clavien-Dindo classification
Time frame: postoperative up to 10-15 years
Adverse events (AEs) related to ePLND
Categorized according to CTCAE version 5.0
Time frame: postoperative up to 10-15 years
Patient-reported outcome measures (PROMs)
tracked using the Expanded Prostate Cancer Index Composite (EPIC)-26 questionnaire Score 1-100 (100 indicates best quality of life score)
Time frame: postoperative up to 10-15 years
Evaluation of risk prediction for nodal invasion
from prostate biopsy results
Time frame: postoperative to the end of the study at 10-15 years
Evaluation of the potential value of unilateral ePLND
Time frame: postoperative to the end of the study at 10-15 years
Started Feb 2025 (actual). Primary completion is estimated for Feb 2027, 24 months after the start.
Of 1,104 non-industry interventional studies with no phase under Prostatic Neoplasms, half reached primary completion within 43 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 87. This study's planned 24 months is below that.
Counting every sponsor, half of 1,162 studies reached it within 43 months; a quarter within 22 and three quarters within 86.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University Hospital, Basel, Switzerland →